

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

SU-DHL-16

RRID:CVCL_1890

Type: Cell Line

Proper Citation

ATCC Cat# CRL-2964, RRID:CVCL_1890

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1890

Proper Citation: ATCC Cat# CRL-2964, RRID:CVCL_1890

Description: Cell line SU-DHL-16 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: B-cell non-Hodgkin lymphoma

Defining Citation: [PMID:19278952](#), [PMID:20215515](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-16

Synonyms: SUDHL16, SuDHL16, SUDHL-16, Stanford University-Diffuse Histiocytic Lymphoma-16, DHL-16

Cross References: CLO:CLO_0037060, EFO:EFO_0002355, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRL-2964, BioSample:SAMN03472751, cancercellines:CVCL_1890, Cell_Model_Passport:SIDM00404, ChEMBL-Cells:ChEMBL4523528, ChEMBL-Targets:ChEMBL4523559, Cosmic:1070713, Cosmic-CLP:1331034, DepMap:ACH-002307, DSMZ:ACC-577, DSMZCellDive:ACC-577, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1331034, GEO:GSM380144,

GEO:GSM1035310, GEO:GSM1670484, GEO:GSM3150256, IGRhCellID:SUDHL16, IZSLER:BS TCL 226, LINCS_LDP:LCL-1135, PharmacDB:SUDHL16_1501_2019, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_1890, PubChem_Cell_line:CVCL_1890, Wikidata:Q54970713

ID: CVCL_1890

Vendor: ATCC

Catalog Number: CRL-2964

Record Creation Time: 20220427T221611+0000

Record Last Update: 20260913T010142+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-16.

No alerts have been found for SU-DHL-16.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in immunology, 16, 1518787.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular cancer therapeutics, 23(5), 683.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.